Drug maker Pharmstandard said Thursday its third-quarter sales soared 84 percent, year-on-year, boosted by an early state tender for anti-cancer drugs.
Sales totaled 14.7 billion rubles, versus 8 billion rubles in the same period last year, the company said in a statement.
It said sales of Johnson & Johnson's anti-cancer drug Velcade totaled 4.8 billion rubles, accounting for one-third of total revenue, after the government shifted its tender to the third quarter from the fourth quarter.
As a result, total sales of third-party products soared 308 percent to stand at 8.1 billion rubles, while sales of the company's own drugs were up 8.3 percent to 6.2 billion rubles.
(Reuters)
Related articles:
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.
